Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 12:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 353 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Bupropion HCl Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1, First-in-human Study of VX-433

NCT07584434
View directory record Official record
Conditions
Narcolepsy Type 1 (NT1)
Interventions
VX-433, Placebo, Midazolam, Bupropion
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 19, 2026, 12:37 PM EDT
Withdrawn Early Phase 1 Interventional

Relapse Prevention in Stimulant Use Disorder

NCT04553263
View directory record Official record
Conditions
Stimulant Use, Relapse, Cognitive Function, ADHD
Interventions
Contrave 8Mg-90Mg Extended-Release Tablet, Bupropion
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 19, 2026, 12:37 PM EDT
Completed Phase 2 Interventional Results available

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

NCT04437485
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions
Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 19, 2026, 12:37 PM EDT
Recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

NCT05646862
View directory record Official record
Conditions
Breast Cancer
Interventions
Inavolisib, Fulvestrant, Alpelisib, Bupropion, Omeprazole, Midazolam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
39
States / cities
Greenbrae, California • Los Alamitos, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 19, 2026, 12:37 PM EDT
Completed Phase 3 Interventional Results available

VA Augmentation and Switching Treatments for Improving Depression Outcomes

NCT01421342
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
1,522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
35
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Oct 19, 2026, 12:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CYP2B6 Genetics and Drug Interactions in Healthy Volunteers

NCT02401256
View directory record Official record
Conditions
Healthy
Interventions
Efavirenz, Bupropion, Rosuvastatin, Montelukast
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 49 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 19, 2026, 12:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Drug Interaction Study With Lu AG06466 in Young Healthy Men

NCT04713254
View directory record Official record
Conditions
Healthy
Interventions
Lu AG06466, Midazolam, Metoprolol, Bupropion
Drug · Other
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 19, 2026, 12:37 PM EDT
Withdrawn Phase 4 Interventional

Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery

NCT02616315
View directory record Official record
Conditions
Weight Regain Post Bariatric Surgery
Interventions
Naltrexone HCl/Bupropion HCl Placebo, Naltrexone HCl/Bupropion HCl
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 19, 2026, 12:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants

NCT02735603
View directory record Official record
Conditions
Heart Repolarization
Interventions
Naltrexone HCl/bupropion HCl, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Oct 19, 2026, 12:37 PM EDT
Completed Phase 2 Interventional

A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression

NCT00624858
View directory record Official record
Conditions
Depression
Interventions
naltrexone SR 32 mg/ bupropion SR 360 mg daily
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Oct 19, 2026, 12:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia

NCT00218218
View directory record Official record
Conditions
Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder, Schizophrenia
Interventions
Transdermal Nicotine Patch, 21 mg transdermal nicotine, placebo patch
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 19, 2026, 12:37 PM EDT
Recruiting Phase 4 Interventional

Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

NCT04604509
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Bupropion Hydrochloride Controlled-release, Nicotine Replacement, Questionnaire Administration, Tobacco Cessation Counseling, Varenicline
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 12:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Contingency Management for Smoking Cessation in Homeless Smokers

NCT01789710
View directory record Official record
Conditions
Smoking, Homeless Persons
Interventions
Bupropion, Nicotine replacement therapy, Contingency Management
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 19, 2026, 12:37 PM EDT
Completed Phase 2 Interventional

Effectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals

NCT00249509
View directory record Official record
Conditions
Marijuana Abuse
Interventions
Nefazodone, Bupropion
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 19, 2026, 12:37 PM EDT
Completed Phase 1 Interventional Results available

Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM)

NCT00285584
View directory record Official record
Conditions
HIV Infections, Depression
Interventions
Bupropion, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 19, 2026, 12:37 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effectiveness of Bupropion for Smokers Recovering From Alcohol Dependence

NCT00304707
View directory record Official record
Conditions
Smoking Cessation, Alcohol-Related Disorders
Interventions
Bupropion, placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 70 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 19, 2026, 12:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Framing Messages for Smoking Cessation With Bupropion - 6

NCT00104598
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Bupropion, Smoking Abstinence Program
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
252 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 9, 2013 · Synced Oct 19, 2026, 12:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion

NCT02085967
View directory record Official record
Conditions
Healthy Subjects
Interventions
rifampin 600 mg, itraconazole 200 mg, midazolam 2 mg with bupropion 75 mg, E2006
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 19, 2026, 12:37 PM EDT
Completed Phase 4 Interventional

Dissemination of Tobacco Tactics for Hospitalized Smokers

NCT01309217
View directory record Official record
Conditions
Smoking Cessation
Interventions
Tobacco Tactics Intervention, Usual Care
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1,528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Grand Rapids, Michigan • Livonia, Michigan • Muskegon, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 19, 2026, 12:37 PM EDT
Completed Phase 4 Interventional

Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease

NCT00181818
View directory record Official record
Conditions
Smoking, Myocardial Infarction, Unstable Angina, Cardiovascular Disease
Interventions
bupropion SR (sustained-release)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2005 · Synced Oct 19, 2026, 12:37 PM EDT
Not yet recruiting Phase 2 Interventional

The BAARD Study : Evaluating a Computerized Approach to Treatment Selection in Older Adults With Treatment Resistant Depression.

NCT07810738
View directory record Official record
Conditions
Late Life Treatment Resistant Depression, Depression - Major Depressive Disorder, Treatment Resistant Depression
Interventions
Aripiprazole Augmentation, Bupropion Augmentation
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 12:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease

NCT02360644
View directory record Official record
Conditions
Chronic Kidney Diseases, Deficiency, Vitamin D
Interventions
Cholecalciferol
Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
2
States / cities
Aurora, Colorado • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 19, 2026, 12:37 PM EDT
Withdrawn Phase 2 Interventional

Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis

NCT07171112
View directory record Official record
Conditions
Pancreatitis, Chronic, Pancreatitis, Acute, Recurrent Acute Pancreatitis, Smoking (Tobacco) Addiction
Interventions
Standard Varenicline Dosing (1 mg BID), Bupropion 150 mg twice daily, Increased Varenicline Dosing (1mg TID)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 19, 2026, 12:37 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Maintaining Nonsmoking: Older Smokers - 1

NCT00086385
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Nicotine polacrilex, Bupropion
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years and older
Enrollment
403 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Oct 19, 2026, 12:37 PM EDT